Current factor IX replacement options for hemophilia B and the challenges ahead.
Massimo FranchiniMarco ZaffanelloDaniele FocosiPublished in: Expert opinion on pharmacotherapy (2023)
The recent introduction of recombinant EHL FIX products has represented a major advance in the therapeutic management of hemophilia B patients, permitting both a reduction of treatment burden and improving patients' compliance to prophylaxis and, ultimately, quality of life.